Assembly Biosciences (ASMB) to Release Earnings on Thursday

Assembly Biosciences (NASDAQ:ASMB) is anticipated to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($2.12) per share and revenue of $7.05 million for the quarter.

Assembly Biosciences Price Performance

ASMB stock opened at $10.85 on Thursday. The stock’s fifty day simple moving average is $13.13 and its two-hundred day simple moving average is $15.21. Assembly Biosciences has a 1-year low of $10.27 and a 1-year high of $19.93.

Insider Activity at Assembly Biosciences

In related news, Director Michael Houghton acquired 3,202 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The shares were bought at an average cost of $15.61 per share, for a total transaction of $49,983.22. Following the purchase, the director now owns 3,202 shares in the company, valued at $49,983.22. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 5.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “neutral” rating on shares of Assembly Biosciences in a research report on Friday, December 27th.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.